ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.680,20
-0,25%
S&P 500
5.307,01
-0,27%
Dow Jones
39.671,04
-0,51%
Euro vs US Dollar
1,08266
0,01%
Bitcoin
69.352,85
0,37%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Kaleido Biosciences Inc (KLDO)

  7. Kaleido Biosciences Inc (KLDO) News

KLDO

Kaleido Biosciences (KLDO)

Kaleido Biosciences Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:KLDO
DatumZeitQuelleÜberschriftSymbolFirma
06/05/202214h16Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(b) (15-12b)NASDAQ:KLDOKaleido Biosciences Inc
02/05/202212h20Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:KLDOKaleido Biosciences Inc
27/04/202211h03TipRanksAnalysts Offer Insights on Healthcare Companies: and Kaleido Biosciences (KLDO)NASDAQ:KLDOKaleido Biosciences Inc
25/04/202222h43Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:KLDOKaleido Biosciences Inc
25/04/202222h41Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:KLDOKaleido Biosciences Inc
18/04/202215h25Edgar (US Regulatory)Notification Filed by a National Securities Exchange to Report the Removal From Listing and Registration of Matured , Redeemed or Retired Securities (25)NASDAQ:KLDOKaleido Biosciences Inc
08/04/202215h26Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KLDOKaleido Biosciences Inc
04/04/202213h45TipRanksKaleido Biosciences (KLDO) was Downgraded to a Hold Rating at Chardan CapitalNASDAQ:KLDOKaleido Biosciences Inc
16/03/202213h30GlobeNewswire Inc.Radius Health Announces Leadership AppointmentsNASDAQ:KLDOKaleido Biosciences Inc
09/03/202222h26Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KLDOKaleido Biosciences Inc
02/03/202222h16Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KLDOKaleido Biosciences Inc
02/03/202222h11Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KLDOKaleido Biosciences Inc
28/02/202215h00PR Newswire (US)Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory AffairsNASDAQ:KLDOKaleido Biosciences Inc
15/02/202216h05PR Newswire (US)INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANTNASDAQ:KLDOKaleido Biosciences Inc
09/02/202215h25Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:KLDOKaleido Biosciences Inc
28/01/202222h44Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KLDOKaleido Biosciences Inc
21/01/202217h04GlobeNewswire Inc.Kaleido Biosciences to Present Updated Data of KB295 In Ulcerative Colitis at the 2022 Crohn’s and Colitis CongressNASDAQ:KLDOKaleido Biosciences Inc
18/01/202223h16Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KLDOKaleido Biosciences Inc
18/01/202223h13Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KLDOKaleido Biosciences Inc
18/01/202223h12Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KLDOKaleido Biosciences Inc
18/01/202223h10Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KLDOKaleido Biosciences Inc
16/12/202123h19Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KLDOKaleido Biosciences Inc
16/12/202123h17Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:KLDOKaleido Biosciences Inc
06/12/202113h30GlobeNewswire Inc.Kaleido Biosciences Announces Expansion of Collaboration with Janssen to Explore Potential of Microbiome Metabolic Therapies (MMT™) to Prevent Childhood-Onset of Atopic, Immune and Metabolic ConditionsNASDAQ:KLDOKaleido Biosciences Inc
15/11/202113h30GlobeNewswire Inc.Kaleido Biosciences to Participate in the Piper Sandler 33rd Annual Virtual Healthcare ConferenceNASDAQ:KLDOKaleido Biosciences Inc
10/11/202113h30GlobeNewswire Inc.Kaleido Biosciences to Appoint Dr. Alison Long as Chief Medical OfficerNASDAQ:KLDOKaleido Biosciences Inc
01/11/202112h30GlobeNewswire Inc.Kaleido Biosciences Reports Third Quarter 2021 Financial ResultsNASDAQ:KLDOKaleido Biosciences Inc
13/10/202116h11PR Newswire (US)Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate ChangeNASDAQ:KLDOKaleido Biosciences Inc
12/10/202113h30GlobeNewswire Inc.Kaleido Biosciences to Participate in the Jefferies Virtual Next Generation IBD Therapeutics SummitNASDAQ:KLDOKaleido Biosciences Inc
05/10/202113h00GlobeNewswire Inc.Kaleido Biosciences Announces New Clinical and Preclinical Data Supporting Advancement of KB295 to a Phase 2 Clinical Study in Mild-to-Moderate Ulcerative ColitisNASDAQ:KLDOKaleido Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:KLDO

Kürzlich von Ihnen besucht

TG
DBK
Deutsche Bank
USOTC
BASFY
BASF (QX)
AMEX
XLE
Energy Select Sector SPDR
NYSE
MCD
McDonalds
CCOM
US30
US 30
TG
D7G
Nel ASA
NASDAQ
AAPL
Apple
NYSE
NKE
Nike
TG
DTE
Deutsche Telekom
NASDAQ
TSLA
Tesla
COIN
SOLUSD
Solana
TG
BAS
BASF
NASDAQ
AMZN
Amazon.com
NASDAQ
NVDA
NVIDIA
TG
MBG
MercedesBenz
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten